title: Reply to E.C. Smyth et al and E. Elimova et al.
authors.affiliation: Centre Hospitalier Universitaire Toulouse, Toulouse, France guimbaud.r@chu-toulouse.fr.
authors.forename: Rosine
authors.initials: R
authors.lastname: Guimbaud
authors.affiliation: Institut Mutualiste Montsouris, Paris, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Louvet
authors.affiliation: Val d'Aurelle, Montpellier, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Ychou
authors.affiliation: Centre Hospitalier Universitaire Reims, Reims, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouché
authors.affiliation: Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004943:Esophagogastric Junction / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*